Thus, ESR1 expression may depend on an open chromatin environment at the distal enhancer in addition to the promoter, and therapies that convert the distal region to a closed state can significantly impact ERα status in breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.